Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
RydaptⓇ - Multi-targeted kinase inhibitor
NCT03591510 (CPKC412A2218)
Indication
Acute myeloid leukemia, pediatrics
Phase 2
Phase
Patients
20
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid
leukemia (AML)
Read-out
Milestone(s)
2026
Publication
TBD
References
Abbreviations
Other
76 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation